昭衍新药：预计2025年净利润同比增加214%到371%

Core Viewpoint - Zhaoyan New Drug (603127) expects a net profit attributable to shareholders of approximately 233 million to 349 million yuan in 2025, representing a year-on-year increase of about 214% to 371% [1] Group 1 - The increase in net profit is driven by the rise in market prices of biological assets and the natural growth appreciation of the assets [1] - The dual factors of market price increase and asset appreciation contribute positively to the company's performance [1]